Saturday 17 October 2026
Export KNSA’s income statement to Excel — free account
Kiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.
78.59
1.35
−1.69%
Follow KNSA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
8 | 4 | 3 | — | — | — | — | — | — | — |
P/E ratio |
51.56 | 0.00 | 97.53 | 5.47 | 0.00 | — | — | — | — | — |
P/S ratio |
4.52 | 3.34 | 4.80 | 4.55 | 0.00 | — | — | — | — | — |
Altman Z-Score |
10.35 | 5.66 | 8.00 | 9.38 | 4.80 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
5.08 | 2.40 | 4.64 | 6.00 | (5.64) | — | — | — | — | — |
P/FCF ratio |
22.42 | 55.34 | 97.89 | 177.86 | 0.00 | — | — | — | — | — |
Beneish M-Score |
(3.16) | (2.43) | (2.01) | 4.22 | — | — | — | — | — | — |
P/Operating CF |
56.79 | 75.27 | 300.16 | (86.55) | (42.74) | — | — | — | — | — |
P/B ratio |
5.39 | 3.22 | 2.96 | 2.53 | 4.36 | — | — | — | — | — |
Price to Tangible BV |
5.54 | 3.35 | 3.08 | 2.65 | 4.87 | — | — | — | — | — |
EV/Sales |
3.91 | 2.76 | 4.04 | 3.68 | 0.00 | — | — | — | — | — |
EV/EBITDA |
33.60 | 0.00 | 0.00 | 66.63 | 0.00 | — | — | — | — | — |
EV/Operating CF |
19.18 | 45.51 | 82.09 | 139.71 | (4.95) | — | — | — | — | — |
EV/FCF |
19.39 | 45.80 | 82.33 | 144.02 | (4.26) | — | — | — | — | — |
Quick Ratio |
3.09 | 2.84 | 3.58 | 4.32 | 4.15 | 10.16 | 8.39 | 7.22 | 2.62 | 24.36 |
Current Ratio |
3.79 | 3.30 | 4.34 | 5.16 | 4.38 | 10.46 | 8.68 | 7.37 | 2.70 | 24.47 |
Net Debt/EBITDA |
(5.26) | 5.55 | 9.03 | (15.66) | 1.18 | 2.09 | 1.39 | 2.85 | 0.70 | 2.34 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.01 | 0.76 | 0.55 | 0.64 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
2.34 | (0.59) | 0.94 | 0.03 | 0.80 | 0.85 | 0.98 | 0.78 | 0.77 | 0.91 |
Capex/Depreciation |
(1.01) | (0.15) | (0.06) | (0.01) | (8.67) | (0.12) | (1.55) | (18.50) | (2.46) | (0.14) |
| 11.73% | (9.85%) | 3.37% | 63.10% | (63.55%) | (60.06%) | (64.15%) | (108.91%) | 112.39% | 41.53% | |
| 8.78% | (7.80%) | 2.86% | 52.96% | (54.24%) | (53.44%) | (56.16%) | (55.88%) | (124.80%) | (46.12%) | |
ROIC |
31.44% | (14.63%) | (6.77%) | 2.97% | (3,451.96%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
15.13% | (18.63%) | 6.60% | 92.77% | (102.25%) | (52.83%) | (73.51%) | (37.19%) | (217.70%) | (44.30%) |
Average Days of Receivables |
8.40 | 35.98 | 28.72 | 20.99 | 37.74 | — | — | — | — | — |
Research and Development Expense of Revenue |
14.29% | 26.37% | 28.16% | 29.74% | 257.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
28.97% | 39.70% | 47.89% | 44.49% | 222.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.03 | 0.04 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.46% | 7.25% | 10.05% | 11.41% | 65.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.11 | 0.13 | 0.15 | 0.18 | 0.18 | — | — | — | — | — |
Graham Number |
11.73 | 0.00 | 5.17 | 18.42 | 0.00 | — | — | — | — | — |
Earnings Yield |
1.94% | (3.08%) | 1.03% | 18.28% | (19.54%) | — | — | — | — | — |
Free Cash Flow Yield |
4.46% | 1.81% | 1.02% | 0.56% | (18.18%) | — | — | — | — | — |
Revenue per Share |
9.13 | 5.93 | 3.86 | 3.17 | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
1.86 | 0.36 | 0.19 | 0.08 | (1.84) | (2.21) | (2.93) | (2.74) | (27.75) | (83.56) |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | (0.30) | 0.00 | (0.06) | (0.18) | (0.04) | (0.01) |
Free Cash Flow per Share |
1.84 | 0.36 | 0.19 | 0.08 | (2.14) | (2.21) | (2.99) | (2.92) | (27.78) | (83.57) |
Cash per Share |
5.58 | 3.41 | 2.95 | 2.75 | 2.66 | 5.23 | 4.32 | 10.40 | 25.23 | 214.27 |
Shareholders Equity per Share |
7.65 | 6.14 | 6.26 | 5.71 | 2.70 | 5.04 | 4.17 | 9.45 | 16.61 | 206.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.65 | 6.14 | 6.26 | 5.71 | 2.70 | 5.04 | 4.17 | 9.45 | 16.61 | 206.97 |
Free Cash Flow |
136.42 | 25.44 | 13.17 | 5.79 | (146.71) | (136.81) | (161.57) | (86.30) | (50.29) | (21.87) |
Working Capital |
387.99 | 231.18 | 212.63 | 195.99 | 151.62 | 301.40 | 213.80 | 271.20 | 29.67 | 54.03 |
Capital Expenditures |
(1.57) | (0.25) | (0.13) | (0.01) | (20.41) | (0.28) | (3.20) | (5.29) | (0.07) | 0.00 |
Net Current Asset Value |
331.15 | 189.68 | 188.81 | 179.54 | 148.68 | 295.72 | 212.52 | 271.05 | 29.67 | 54.03 |
EV/EBIT |
34.27 | 0.00 | 0.00 | 83.01 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
39.64 | 0.00 | 0.00 | 102.51 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.80 | 2.56 | 3.19 | 1.45 | 0.83 | 0.59 | 0.32 | 0.05 | 0.22 | 0.26 |
Cash ROIC |
13.90% | 3.73% | 2.04% | 0.99% | (39.95%) | (21.52%) | (35.22%) | (14.71%) | (66.41%) | (19.84%) |
Accounts Receivable Turnover |
23.64 | 13.44 | 15.93 | 26.46 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
38.20 | 11.84 | 4.14 | 4.69 | 7.68 | 1.23 | 0.39 | 0.05 | 0.04 | 0.03 |
Inventory Turnover |
1.91 | 2.12 | 1.27 | 1.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
9.53 | 12.22 | 90.09 | 125.93 | 74.93 | 48.25 | 633.71 | 13,933.81 | 15,877.50 | 3,517.27 |
Days of Inventory on Hand |
257.96 | 157.98 | 340.03 | 344.34 | 147.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
28.66 | 31.50 | 16.96 | 8.32 | — | — | — | — | — | — |
Average Payables |
2.03 | 5.14 | 8.07 | 4.88 | 1.19 | 3.10 | 8.31 | 6.07 | 0.72 | 0.72 |
Average Inventory |
40.63 | 28.74 | 26.36 | 12.64 | — | — | — | — | — | — |
Average Assets |
672.09 | 553.44 | 493.00 | 346.24 | 291.13 | 302.00 | 288.25 | 184.73 | 51.98 | 51.98 |
Average Common Equity |
503.02 | 438.64 | 417.49 | 290.59 | 248.49 | 268.68 | 252.35 | 94.78 | (57.72) | (57.72) |
Columns are period end dates